Annual health funding likely to lag behind rising costs
GPs also warn patient fees may need to rise this year to cover costs.
Photo:
RNZ
picture id="4K747KF_HEALTH_WEB_png" crop="16x10" layout="thumbnail"]
Wellington toddler Sophie-Grace has cystic fibrosis, which means she is regularly admitted to hospital with lung infections.
Her dad Ben Butler-Hogg said the family had been hoping
Budget 2025
would include a further cash injection for Pharmac, to allow it to increase access to the drug Trikafta for two to five-year-olds, like her.
But it was not to be.
"The medication that we get today will remove burden from our infrastructure," Butler-Hogg said.
"The sooner we can intervene with our children, the better quality of life they've got.
"I want my daughter to get to adulthood without needing a transplant."
The drug-buying agency did get a funding boost of $604 million over four years following last year's Budget, but that has been largely already committed.
Meanwhile, GPs warn patient fees may need to rise this year to cover costs.
Dr Angus Chambers.
Photo:
Supplied
Dr Angus Chambers, from the General Practice Owners Association, said Health NZ had already indicated its annual funding hike for doctors was likely to lag behind rising costs.
"Unless there's a surprise in this annual uplift at capitation, we're pretty worried that we will see a substantial upward pressure in patient fees, of that 10 percent mark."
Overall, primary and community care had a boost of about $600m, with most initiatives already announced.
Most of it was paid for out of the $420m set aside for pay equity claims - wiped out by a sudden law change earlier this month.
General Practice New Zealand chief executive Maura Thompson said axing the claim for primary care nurses would make it even tougher to recruit and retain staff.
"The celebration of savings comes at the expense of fair pay for women. So the pay equity claim for primary care nurses being terminated is a huge disappointment, and will have a real impact, unfortunately."
The Association of Salaried Medical Specialists represents senior hospital doctors and dentists who are locked in a pay dispute with Health NZ.
Its policy and research director Harriet Wild said the positive benefit of funding increases in areas like urgent care and cancer medicine were not enough to solve the staffing crisis.
"It's a departure lounge Budget because we are facing a recruitment and retention crisis across the board.
"Everyone will continue to leave, whether that's specialists, trainee doctors, nurses, workers across the health sector, either heading into private, or heading straight overseas."
Health Minister Simeon Brown said the government's record investment over three budgets was already delivering results - in terms of more elective surgeries, GP appointments and other critical healthcare services.
Sign up for Ngā Pitopito Kōrero
,
a daily newsletter curated by our editors and delivered straight to your inbox every weekday
.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
RNZ News
8 hours ago
- RNZ News
The Panel with Ed Amon and Madison Burgess-Smith Part 2
Photo: 123RF Tonight on The Panel, Wallace Chapman is joined by panellists Ed Amon and Madison Burgess-Smith. This half hour the panel hears about the ins and outs of collecting rainwater for drinking and why your council may not approve and they talk to Trevor Goodin, an Oamaru business man who has stepped up to provide a shuttle hospital service for the needy.
RNZ News
9 hours ago
- RNZ News
Ministry for Primary Industries to review controls for tomato virus
Tomato brown rugose fruit virus. Photo: Tomatoes NZ Ministry for Primary Industries says it will review its current controls after Australia changed its strategy to deal with a highly contagious virus affecting tomatoes, capsicums and chillies. Across the Tasman , biosecurity experts and industry representatives have declared tomato brown rugose virus not technically feasible to eradicate and moved to a management strategy. 'Tomato virus' was first detected in South Australia last August and has also been found on a farm in Victoria. It is not harmful to humans but infected fruit can ripen irregularly or be deformed. It can also reduce crop yields by 70 percent. Biosecurity New Zealand deputy director-general Stuart Anderson said MPI had controls in place that were "working well for New Zealand and prevented any issues for our tomato growers after the discovery of tomato brown rugose fruit virus (ToBRFV) at sites in South Australia last August". He said a ban on all Australian tomato imports remained in place, even though only Australian tomatoes from Queensland, an area free from the virus, were imported here. "We made the decision to suspend imports from all Australian states out of an abundance of caution. As part of the actions we took, tomato and capsicum seeds from Australia require testing for the virus prior to arrival in New Zealand, a requirement already in place for other countries where the virus is present. That requirement remains. "Although Australia has announced they will no longer be pursuing eradication, all of the controls that have been in place to limit spread of the virus remain." There was nothing to suggest the virus was here but MPI's chief biosecurity officer would conduct a review of what Australia has in place to manage the risk, and New Zealand's import rules "to ensure that our settings remain reasonable", he said. "New Zealand imports Australian capsicums from Queensland. ToBRFV has not been reported in any parts of Australia in capsicums and has not been detected in Queensland. We are closely monitoring the situation in Australia and if there is any significant change in distribution, or which crops it is affecting, we will review the current import rules. "We continue to work closely with New Zealand's tomato sector. We have asked New Zealand industry representatives to assist by sharing any information they have that may inform our decision-making. We also meet regularly with Australian officials to maintain a continued understanding of the situation." MPI said growers should continue to check their biosecurity practices. "As always... be vigilant and contact us on our pests and diseases hotline (0800 80 99 66) if [you] notice problems with [your] tomatoes". Sign up for Ngā Pitopito Kōrero , a daily newsletter curated by our editors and delivered straight to your inbox every weekday.
RNZ News
10 hours ago
- RNZ News
Health Committee hears submissions on Medicines Amendment Bill
The Medicines Amendment Bill will continue to be considered by the Health Committee over the next two months. Photo: 123RF MPs on Parliament's Health Select Committee were told by the public this week that, while the government's Medicines Amendment Bill is a step in the right direction, changes are still needed to ensure it balances safety with efficiency. The bill, which amends the Medicines Act 1981, received its first reading in April, and is a component of a wider push by the government to loosen burdensome regulation across sectors. Under current settings, prescription medicines can take a long time to be approved, funded, and made available to the New Zealanders that need them. Historically, we have ranked well below the OECD average for access to medicines. In his oral submission on the bill, New Zealand Initiative chief economist Dr Eric Crampton suggested that New Zealand simply wasn't a desirable target market for medicine companies. "We are a small, relatively poor country at the far end of the world that will not be at the top of anyone's agenda in getting their regulatory affairs team to deal with paperwork… It can take years after a drug has been approved by at least two markets overseas before anybody puts it into the New Zealand approvals process." In his submission, Crampton mentioned the concept of an "invisible graveyard," referring to the people who may have died or been harmed as a consequence of not having access to unapproved medicines. The Medicines Amendment Bill seeks to shake up the status quo, improving patients' access to medication by doing three things. Primarily it would introduce what has been dubbed as 'the rule of two', whereby if a medication has been approved for use in two recognised overseas regulators, Medsafe (New Zealand's medicines regulator), can bypass its usual, often lengthy, assessment process. The government hopes this will reduce the time it takes for new medicines to reach patients. The recognised overseas regulators are those from Australia, Canada, the EU, UK, USA, Switzerland and Singapore. As well as these fast-tracking medicine approvals, the bill also expands the power to prescribe medicine to a wider range of healthcare professionals, such as nurse practitioners, midwives, dentists, and optometrists, so long as the medication falls within their scope of practice. Thirdly, the bill updates some of the settings around the Medicines Classification Committee, which makes recommendations to the Minister of Health around how new medicines should be classed. This week the Health Committee also heard from Dr Graeme Jarvis, CEO of Medicines New Zealand, which represents pharmaceutical companies. While in support of the bill's intent, he told MPs, it needs refinement in order to better achieve its goal outcomes. When asked by Labour's spokesperson for Health Ayesha Verrall, why he was sceptical of the automatic approvals that Dr Crampton had suggested to the committee earlier, Dr Jarvis suggested that doing so would create "unintended consequences around parallel importing and other activities". "People flood the market, and the product may not necessarily be what you think it is, you may end up with counterfeit products coming in. There is no clawback for the regulator to go after a sponsor who has been acting in an unsatisfactory manner." When New Zealand lawmakers look outward for policy inspiration, they tend not to just throw a dart at a map on the wall and hope for the best. There are generally agreed comparable countries, commonly drawn on as case studies for good lawmaking here, which vary depending on the topic. The Medicines Amendment Bill's 'rule of two' provisions reflects this tradition, using a familiar set of jurisdictions in its list of recognised overseas regulators. Members of the Wellington Community Justice Project, a volunteer group made up of Victoria University law students, suggested to the Health Committee that while these overseas regulators have been historically reliable, that does not mean they always will be. "While the bill allows the minister to make rules for verification through secondary legislation so they can be refined to reflect changes in best international practice, we feel as though there needs to be something within the text of the bill itself, ensuring that the regulatory authorities themselves are regularly assessed and upheld to the standards of best international practice," the students told the committee. They went on to cite the current changes being made to the United States FDA, which has long been the world leader in approving medicine. "The FDA's placement on this list, most notably for the reason that the FDA is currently headed by RFK Jr, a health secretary who has been described as a conspiracy theorist, and relevant to this bill, has cancelled or frozen billions of dollars of research grants for the development of the medicines. Clearly, this bill [will outlast] RFK Junior's appointment. However, this example illustrates the need for a process to review the regulatory authorities in Section 22A, so when the questions arise about jurisdictions' suitabilities to be on the two-step verification process, these are able to be addressed." The Medicines Amendment Bill will continue to be considered by the Health Committee over the next two months, before being reported back to the House by the 9 August. You can listen to the audio version of this story by clicking the link near the top of the page. *RNZ's The House, with insights into Parliament, legislation and issues, is made with funding from Parliament's Office of the Clerk.
